Organon & (US:OGN) ZACKSยท2024-06-20 23:05Core Viewpoint - Investors should monitor recent shifts in analyst projections for Organon, as these modifications often indicate changing near-term business trends and reflect analyst optimism about the company's profitability [1] Company Performance - Organon's shares have decreased by 7.33% over the last month, underperforming the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59% [2] - The latest trading session saw Organon ending at $20.45, marking a +0.49% adjustment from the previous day's close, outperforming the S&P 500's daily loss of 0.25% [7] Earnings Estimates - The full-year Zacks Consensus Estimates for Organon project earnings of $4.42 per share and revenue of $6.37 billion, representing year-over-year changes of +6.76% and +1.67%, respectively [3] - The upcoming earnings release is expected to show an EPS of $1.18, indicating a 9.92% decline compared to the same quarter last year, with revenue estimated at $1.63 billion, up 1.16% from the prior-year quarter [8] Valuation Metrics - Organon currently has a PEG ratio of 0.86, compared to the Medical Services industry's average PEG ratio of 1.53 [5] - The company holds a Forward P/E ratio of 4.6, which is a discount compared to the industry's average Forward P/E of 19.08 [10] Industry Ranking - The Medical Services industry, which includes Organon, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [11]